All In MedTech

Device Trial Radar · NCT00968994

Trial of exSALT SD7™ Compared to Xeroform® Petrolatum Dressing for the Management of Partial Thickness Donor Sites

A Randomized, Site-Matched, Controlled Trial of exSALT SD7™ Compared to Xeroform® Petrolatum Dressing for the Management of Partial Thickness Donor Sites

Last checked: Nov 19, 2026Latest source record: Dec 24, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

25

Planned (sponsor's estimate)

Start

Dec 2009

Primary completion

Dec 2010

Study completion Jan 2011

Sponsor

Lead sponsor
Exciton Technologies Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Alberta Heritage Foundation for Medical Research; Epidemiology Coordinating and Research Centre, Canada; Smart Medical Research Inc.
First posted
Aug 31, 2009

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, controlled trial is designed to evaluate split-thickness donor sites treated with exSALT SD7™ compared to donor sites treated with Xeroform®. For the purpose of this study, subjects enrolled will have selected donor sites or portions of donor sites designated as "Test Sites." The selected locations will be randomly assigned treatment with either the Test Dressing or the Control Dressing. The primary objective of the trial will be to quantify the proportion of the donor sites in each group that are healed at 10 and 14 days. Secondary objectives will include: time to re-epithelialization, pain with dressing changes and mobilization, ease of use, resource utilization and safety, as well as quality of healing and overall cosmetic result. A total of 25 subjects will be enrolled in the trial. The trial duration will be 12 weeks. For the purposes of this trial, healing will be defined as ≥ 90% re-epithelialization and must be visually confirmed by the investigator or designate and two other people (i.e., research nurse, burn resident, member of the Wound Care Team). The maximum time to evaluate healing will be 14 days +/-2 days. A final visit will be conducted at 12 weeks for safety and to evaluate the quality of healing.

Conditions

  • Wound Healing
  • Wound Infection

Interventions

  • The exSALT™ SD7 Wound DressingDevice

    The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.

  • Xeroform® Petrolatum DressingDevice

    Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the proportion of donor sites healed.Time frame: 10 days
  2. Evaluate the proportion of donor sites healed.Time frame: 14 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Alberta Hospital

    Edmonton, Alberta, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.